

Arnold S Kristof

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8608183/publications.pdf>

Version: 2024-02-01

35
papers

1,234
citations

394421

19
h-index

377865

34
g-index

37
all docs

37
docs citations

37
times ranked

2010
citing authors

#	ARTICLE	IF	CITATIONS
1	Mitogen-activated Protein Kinases Mediate Activator Protein-1-dependent Human Inducible Nitric-oxide Synthase Promoter Activation. <i>Journal of Biological Chemistry</i> , 2001, 276, 8445-8452.	3.4	150
2	Effect of Probiotics on Incident Ventilator-Associated Pneumonia in Critically Ill Patients. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1024.	7.4	94
3	Maximal Oxygen Uptake and Severity of Disease in Lymphangiomyomatosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 168, 1427-1431.	5.6	89
4	Inhibition of Mammalian Target of Rapamycin Augments Lipopolysaccharide-Induced Lung Injury and Apoptosis. <i>Journal of Immunology</i> , 2012, 188, 4535-4542.	0.8	84
5	Reactive Oxygen Species Regulation of Autophagy in Skeletal Muscles. <i>Antioxidants and Redox Signaling</i> , 2014, 20, 443-459.	5.4	83
6	Stimulation of Signal Transducer and Activator of Transcription-1 (STAT1)-dependent Gene Transcription by Lipopolysaccharide and Interferon- γ Is Regulated by Mammalian Target of Rapamycin. <i>Journal of Biological Chemistry</i> , 2003, 278, 33637-33644.	3.4	80
7	Angiopoietin-1 promotes endothelial cell proliferation and migration through AP-1-dependent autocrine production of interleukin-8. <i>Blood</i> , 2008, 111, 4145-4154.	1.4	80
8	Low systemic vascular resistance state in patients undergoing cardiopulmonary bypass. <i>Critical Care Medicine</i> , 1999, 27, 1121-1127.	0.9	71
9	Protein Delivery in the Intensive Care Unit: Optimal or Suboptimal?. <i>Nutrition in Clinical Practice</i> , 2017, 32, 58S-71S.	2.4	48
10	LY303511 (2-Piperazinyl-8-phenyl-4 <i>H</i> -1-benzopyran-4-one) Acts via Phosphatidylinositol 3-Kinase-Independent Pathways to Inhibit Cell Proliferation via Mammalian Target of Rapamycin (mTOR)- and Non-mTOR-Dependent Mechanisms. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 314, 1134-1143.	2.5	44
11	Inactivation of Mammalian Target of Rapamycin Increases STAT1 Nuclear Content and Transcriptional Activity in β - and Protein Phosphatase 2A-dependent Fashion. <i>Journal of Biological Chemistry</i> , 2009, 284, 24341-24353.	3.4	41
12	mTORC2 Balances AKT Activation and eIF2 γ Serine 51 Phosphorylation to Promote Survival under Stress. <i>Molecular Cancer Research</i> , 2015, 13, 1377-1388.	3.4	35
13	Biomarkers in critical care nutrition. <i>Critical Care</i> , 2020, 24, 499.	5.8	34
14	Genetics and Gene Expression in Lymphangiomyomatosis. <i>Chest</i> , 2002, 121, 56S-60S.	0.8	30
15	Human Pluripotent Stem Cell-Derived α TSC2 β -Haploinsufficient Smooth Muscle Cells Recapitulate Features of Lymphangiomyomatosis. <i>Cancer Research</i> , 2017, 77, 5491-5502.	0.9	29
16	Albumin and fibrinogen kinetics in sepsis: a prospective observational study. <i>Critical Care</i> , 2021, 25, 436.	5.8	29
17	Phosphatidylinositol 3-Kinase-dependent Suppression of the Human Inducible Nitric-oxide Synthase Promoter Is Mediated by FKHL1. <i>Journal of Biological Chemistry</i> , 2006, 281, 23958-23968.	3.4	28
18	Paradoxical Effects of Rapamycin on Experimental House Dust Mite-Induced Asthma. <i>PLoS ONE</i> , 2012, 7, e33984.	2.5	25

#	ARTICLE	IF	CITATIONS
19	Regulation of ULK1 Expression and Autophagy by STAT1. <i>Journal of Biological Chemistry</i> , 2017, 292, 1899-1909.	3.4	24
20	mTOR Signaling in Lymphangiomyomatosis. <i>Lymphatic Research and Biology</i> , 2010, 8, 33-42.	1.1	21
21	Lymphangiomyomatosis and Tuberous Sclerosis Complex in Quebec. <i>Chest</i> , 2015, 148, 444-449.	0.8	18
22	Regulation of Karyopherin β 1 and Nuclear Import by Mammalian Target of Rapamycin. <i>Journal of Biological Chemistry</i> , 2012, 287, 14325-14335.	3.4	15
23	Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangiomyomatosis. <i>Peptides</i> , 2010, 31, 1511-1516.	2.4	13
24	Downregulation of PERK activity and eIF2 β serine 51 phosphorylation by mTOR complex 1 elicits pro-oxidant and pro-death effects in tuberous sclerosis-deficient cells. <i>Cell Death and Disease</i> , 2018, 9, 254.	6.3	10
25	A review of the effects of three cardioactive agents on the electrical activity from embryonic chick heart cell aggregates: TTX, ACh, and E-4031. <i>Progress in Biophysics and Molecular Biology</i> , 1994, 62, 185-202.	2.9	9
26	Hyperinsulinemic-normoglycemic clamp administered together with amino acids induces anabolism after cardiac surgery. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2016, 311, R1085-R1092.	1.8	9
27	Identification of Tpr and β -actinin-4 as two novel SLK-interacting proteins. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2015, 1853, 2539-2552.	4.1	8
28	Regulation of hexose transport in respiration deficient hamster lung fibroblasts. <i>Journal of Cellular Physiology</i> , 1990, 143, 88-93.	4.1	7
29	Surrogate Humane Endpoints in Small Animal Models of Acute Lung Injury: A Modified Delphi Consensus Study of Researchers and Laboratory Animal Veterinarians*. <i>Critical Care Medicine</i> , 2021, 49, 311-323.	0.9	7
30	Oncogenic effects of urotensin-II in cells lacking tuberous sclerosis complex-2. <i>Oncotarget</i> , 2016, 7, 61152-61165.	1.8	5
31	An Official American Thoracic Society Workshop Report: Translational Research in Rare Respiratory Diseases. <i>Annals of the American Thoracic Society</i> , 2017, 14, 1239-1247.	3.2	4
32	The discovery of novel mechanisms for lymphangiomyomatosis pathogenesis through GWAS: a rarity in rare respiratory disorders. <i>European Respiratory Journal</i> , 2019, 53, 1900863.	6.7	2
33	Regulation of protein kinase β Nuclear Import and Apoptosis by Mechanistic Target of Rapamycin Complex-1. <i>Scientific Reports</i> , 2019, 9, 17620.	3.3	2
34	Novel rare genetic variants in idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2020, 56, 2003252.	6.7	2
35	The initial validation of a novel outcome measure in severe burns- the Persistent Organ Dysfunction +Death: Results from a multicenter evaluation. <i>Burns</i> , 2021, 47, 765-775.	1.9	1